These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 29311431)

  • 1. Evaluation of pH-sensitive fusogenic polymer-modified liposomes co-loaded with antigen and α-galactosylceramide as an anti-tumor vaccine.
    Okazaki S; Iwasaki T; Yuba E; Watarai S
    J Vet Med Sci; 2018 Feb; 80(2):197-204. PubMed ID: 29311431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficiency of pH-sensitive fusogenic polymer-modified liposomes as a vaccine carrier.
    Watarai S; Iwase T; Tajima T; Yuba E; Kono K
    ScientificWorldJournal; 2013; 2013():903234. PubMed ID: 23431260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. pH-sensitive polymer-liposome-based antigen delivery systems potentiated with interferon-γ gene lipoplex for efficient cancer immunotherapy.
    Yuba E; Kanda Y; Yoshizaki Y; Teranishi R; Harada A; Sugiura K; Izawa T; Yamate J; Sakaguchi N; Koiwai K; Kono K
    Biomaterials; 2015 Oct; 67():214-24. PubMed ID: 26222284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of pH-sensitive fusogenic polymer-modified liposomes for development of mucosal vaccines.
    Watarai S; Iwase T; Tajima T; Yuba E; Kono K; Sekiya Y
    Vet Immunol Immunopathol; 2014 Mar; 158(1-2):62-72. PubMed ID: 23790647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pH-sensitive fusogenic 3-methyl-glutarylated hyperbranched poly(glycidol)-conjugated liposome induces antigen-specific cellular and humoral immunity.
    Hebishima T; Yuba E; Kono K; Takeshima SN; Ito Y; Aida Y
    Clin Vaccine Immunol; 2012 Sep; 19(9):1492-8. PubMed ID: 22815149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells.
    Matsuyoshi H; Hirata S; Yoshitake Y; Motomura Y; Fukuma D; Kurisaki A; Nakatsura T; Nishimura Y; Senju S
    Cancer Sci; 2005 Dec; 96(12):889-96. PubMed ID: 16367909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A liposome-based antigen delivery system using pH-sensitive fusogenic polymers for cancer immunotherapy.
    Yuba E; Harada A; Sakanishi Y; Watarai S; Kono K
    Biomaterials; 2013 Apr; 34(12):3042-52. PubMed ID: 23374704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor.
    Ko SY; Ko HJ; Chang WS; Park SH; Kweon MN; Kang CY
    J Immunol; 2005 Sep; 175(5):3309-17. PubMed ID: 16116223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
    Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
    Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dextran derivative-based pH-sensitive liposomes for cancer immunotherapy.
    Yuba E; Tajima N; Yoshizaki Y; Harada A; Hayashi H; Kono K
    Biomaterials; 2014 Mar; 35(9):3091-101. PubMed ID: 24406217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The application of pH-sensitive polymer-lipids to antigen delivery for cancer immunotherapy.
    Yuba E; Kono Y; Harada A; Yokoyama S; Arai M; Kubo K; Kono K
    Biomaterials; 2013 Jul; 34(22):5711-21. PubMed ID: 23639528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sublingual administration of liposomes enclosing alpha-galactosylceramide as an effective adjuvant of allergen immunotherapy in a murine model of allergic rhinitis.
    Suzuki S; Sakurai D; Sakurai T; Yonekura S; Iinuma T; Okuma Y; Ihara F; Arai T; Hanazawa T; Fukuda-Kawaguchi E; Ishii Y; Okamoto Y
    Allergol Int; 2019 Jul; 68(3):352-362. PubMed ID: 30803854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of Peptide-Based Tumor Immunotherapy Using pH-Sensitive Fusogenic Polymer-Modified Liposomes.
    Yoshizaki Y; Yuba E; Komatsu T; Udaka K; Harada A; Kono K
    Molecules; 2016 Sep; 21(10):. PubMed ID: 27681717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oligomannose-coated liposomes as a therapeutic antigen-delivery and an adjuvant vehicle for induction of in vivo tumor immunity.
    Kojima N; Biao L; Nakayama T; Ishii M; Ikehara Y; Tsujimura K
    J Control Release; 2008 Jul; 129(1):26-32. PubMed ID: 18485512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B subunit of Shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity.
    Adotevi O; Vingert B; Freyburger L; Shrikant P; Lone YC; Quintin-Colonna F; Haicheur N; Amessou M; Herbelin A; Langlade-Demoyen P; Fridman WH; Lemonnier F; Johannes L; Tartour E
    J Immunol; 2007 Sep; 179(5):3371-9. PubMed ID: 17709554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broadening the Message: A Nanovaccine Co-loaded with Messenger RNA and α-GalCer Induces Antitumor Immunity through Conventional and Natural Killer T Cells.
    Verbeke R; Lentacker I; Breckpot K; Janssens J; Van Calenbergh S; De Smedt SC; Dewitte H
    ACS Nano; 2019 Feb; 13(2):1655-1669. PubMed ID: 30742405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic TRP2 long-peptide and α-galactosylceramide formulated into cationic liposomes elicit CD8+ T-cell responses and prevent tumour progression.
    Neumann S; Young K; Compton B; Anderson R; Painter G; Hook S
    Vaccine; 2015 Oct; 33(43):5838-5844. PubMed ID: 26363382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentiation of pH-sensitive polymer-modified liposomes with cationic lipid inclusion as antigen delivery carriers for cancer immunotherapy.
    Yoshizaki Y; Yuba E; Sakaguchi N; Koiwai K; Harada A; Kono K
    Biomaterials; 2014 Sep; 35(28):8186-96. PubMed ID: 24969637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galactosylated liposome as a dendritic cell-targeted mucosal vaccine for inducing protective anti-tumor immunity.
    Jiang PL; Lin HJ; Wang HW; Tsai WY; Lin SF; Chien MY; Liang PH; Huang YY; Liu DZ
    Acta Biomater; 2015 Jan; 11():356-67. PubMed ID: 25242652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.